Related Experiment Videos
Fenretinide as an anti-angiogenic agent in neuroblastoma
Domenico Ribatti1, Lizzia Raffaghello, Danilo Marimpietri
1Department of Human Anatomy and Histology, University of Bari Medical School, Policlinico, 11 I-70124 Bari, Italy. ribatti@anatomia.uniba.it
Cancer Letters
|July 26, 2003
Abstract:
Angiogenesis is a critical event in the progression of human neuroblastoma. This mini-review summarizes our literature and experimental data concerning the use of anti-angiogenic molecules, such as TNP-470 and fenretinide, in neuroblastoma treatment.
Insights
Anti-angiogenic molecules like TNP-470 and fenretinide show promise in treating neuroblastoma by inhibiting critical blood vessel growth. This review covers their potential in neuroblastoma therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis.
- Neuroblastoma, a pediatric cancer, relies on angiogenesis for progression.
- Targeting angiogenesis offers a potential therapeutic strategy for neuroblastoma.
Purpose of the Study:
- To review the role of anti-angiogenic molecules in neuroblastoma treatment.
- To summarize literature and experimental data on TNP-470 and fenretinide for neuroblastoma.
Main Methods:
- Literature review of studies on angiogenesis inhibitors in neuroblastoma.
- Analysis of experimental data on TNP-470 and fenretinide efficacy.
- Synthesis of findings regarding anti-angiogenic therapy in neuroblastoma.
Main Results:
- Anti-angiogenic molecules demonstrate potential in controlling neuroblastoma tumor growth.
- TNP-470 and fenretinide are identified as key agents in preclinical and clinical investigations.
- Inhibition of angiogenesis can impede neuroblastoma progression.
Conclusions:
- Anti-angiogenic therapies represent a viable approach for neuroblastoma treatment.
- Further research into TNP-470 and fenretinide is warranted to optimize their clinical application.
- Targeting tumor vasculature is a crucial strategy in managing neuroblastoma.